Method of treating cancer using immune checkpoint inhibitor
AssigneeBristol-Myers Squibb Company
InventorsDemetrios MANEKAS, Joseph GROSSO, Jeffrey A. ANDERSON
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.
Claims28
A method for treating a subject afflicted with a tumor derived from a human papilloma virus (HPV)-positive squamous cell carcinoma head and neck cancer (SCCHN) comprising administering to the subject a flat dose of about 240 mg of nivolumab once every two weeks without regard for the weight of the subject.
A method of treating a subject afflicted with a tumor derived from an HPV-positive SCCHN comprising:
- (i) measuring a level of HPV in a sample of the subject, wherein the subject is positive for HPV;
- and
- (ii) administering to the subject a flat dose of about 240 mg of nivolumab once every two weeks without regard for the weight of the subject.
3-4. (canceled)
(canceled)
8-10. (canceled)
(canceled)
15-31. (canceled)
33-34. (canceled)
(canceled)
39-80. (canceled)
Dependencies are inferred from the claim text.